Group 1 - The report highlights the significant interest from global investors in high-quality A-share companies that have listed in Hong Kong, such as Ningde Times and Midea Group, with Ningde Times raising a total of HKD 41 billion and seeing a premium over its A-share price [2][12][36] - The performance of A-share companies that have recently listed in Hong Kong has been strong, with an average year-to-date increase of 4.6% compared to the overall A-share market's 0.7% [3][36] - The report indicates that the recent trend of A-share companies listing in Hong Kong has positively impacted the A-share market, leading to increased valuations and investor interest in core assets [3][36] Group 2 - The report discusses the structural changes in the Hong Kong IPO market, noting a 92.8% increase in fundraising compared to 2023, with 70 IPOs in 2024 and 27 in 2025 so far [12][18] - It emphasizes the growing importance of Hong Kong as a platform for mainland companies to raise capital, with 41 A-share companies planning to list in Hong Kong in 2025 [20][36] - The report outlines the performance of specific companies post-listing, such as Midea Group and Ningde Times, which have shown strong price movements and have influenced their respective sectors positively [28][34]

作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...

Group 1 - The core viewpoint is that the trend of Chinese companies going public overseas is accelerating, driven by regulatory policies that enhance the efficiency of the listing process and facilitate cross-border financing [2][3][5] - As of May 28, 2025, 35 Chinese companies have listed on US stock exchanges and 20 on Hong Kong exchanges, surpassing the same period last year, with a significant reduction in the approval time for listings [3] - The approval process for the China Securities Regulatory Commission (CSRC) has improved dramatically, with the average review period reduced from over 100 days in 2024 to within 60 days, and a record of 25 days for Ningde Times [3][4] Group 2 - Leading companies like Heng Rui Pharmaceutical and Ningde Times have seen substantial oversubscription rates of 455 times and 151 times, respectively, indicating strong market confidence in Chinese firms [4] - The "A+H" dual financing platform is emerging, with companies like Muyuan Foods and Sany Heavy Industry submitting applications for overseas listings, reflecting a strategic shift towards global resource allocation [4][5] - Regulatory measures such as the "five policies benefiting Hong Kong" and the expansion of the Shanghai-Hong Kong Stock Connect are creating a favorable environment for Chinese companies to access global capital markets [4][5] Group 3 - The regulatory framework is evolving to support overseas listings, with the State Administration of Foreign Exchange proposing to relax restrictions on fund exchange and account usage [5] - The Central Bank is set to expand the Qualified Foreign Limited Partner (QFLP) pilot program and promote data sharing for hard technology companies, enhancing their access to cross-border financing [5] - The capital outflow strategy is shifting from passive selection to strategic layout, with companies increasingly focusing on global supply chain integration and brand internationalization [6]

Group 1 - The pharmaceutical sector in A-shares has experienced a prolonged bear market lasting over three years, with the Shenwan Pharmaceutical and Biological Index declining by 54% during this period [1] - Approximately two-thirds of the existing 600 pharmaceutical funds have a net value below 1 as of May 28, 2023, with the lowest at 0.35 [1] - However, more than half of the pharmaceutical funds achieved positive returns in 2025, with top performers yielding between 47% and 56% [1][2] Group 2 - The core factors driving the recovery of pharmaceutical funds include marginal improvements in the pharmaceutical sector's performance, despite ongoing revenue and profit declines [2][5] - The pharmaceutical sector's revenue is projected to decrease by 0.5% in 2024, with net profit expected to drop by 11% [2] - The overall performance of the pharmaceutical sector showed signs of stabilization in Q1 2025, with a revenue decline of 3.4% and a net profit decrease of 4% [2][5] Group 3 - The pharmaceutical sector's valuation has reached historical lows, making it attractive for investors, with a price-to-earnings ratio of 29x at the beginning of the year [5] - The Shenwan Pharmaceutical and Biological Index has increased by 3.76% from the beginning of the year to May 28, 2023, with notable fluctuations in its performance [6][8] - The recovery in the pharmaceutical sector is driven by investor expectations of stabilization, supported by the release of quarterly reports [8] Group 4 - Innovative drugs are currently the main source of alpha in the pharmaceutical sector, with top-performing funds achieving returns exceeding 40% through active stock selection [9][12] - The top holdings of the Zhongyin Great Health A fund include several leading innovative pharmaceutical companies, all of which saw significant price increases in Q1 2025 [10][12] - The long-term investment strategy of the Zhongyin Great Health A fund focuses on domestic innovative drugs, despite the sector's previous downturn [12] Group 5 - The pharmaceutical sector is expected to benefit from favorable policies supporting innovation, with the domestic innovative drug market entering a harvest phase [18] - The chemical pharmaceutical sub-sector has outperformed due to the market entry of innovative drugs and favorable policy expectations [14][17] - The performance of various pharmaceutical sub-sectors has shown significant differentiation, with innovative drugs presenting clearer investment opportunities [17][19]

Industry Investment Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The ASCO conference has showcased significant data from several domestic innovative drugs, highlighting opportunities for innovation and performance resonance [1][4] - The report emphasizes the increasing competitiveness and international influence of Chinese pharmaceutical companies, with a record number of original research results presented at ASCO [4][5] - The report suggests a positive outlook for the innovative drug sector, driven by favorable policies and low valuations compared to historical averages [4] Summary by Sections Market Performance - The Hang Seng Index fell by 2.4% during the week, while the Hang Seng Healthcare Index decreased by 1.0%, ranking 7th among 12 industry indices [4][22] - Sub-industry performance varied, with life sciences tools and services up by 3.4%, and biotechnology down by 4.9% [4][22] Company Ratings and Valuations - The report provides a detailed valuation summary for various companies, with most rated as "Buy" and a few as "Neutral" or "Sell" [3][42] - Notable companies with "Buy" ratings include: - AstraZeneca (AZN US) with a target price of 93.30 and a current price of 70.96 [3] - BeiGene (6160 HK) with a target price of 208.80 and a current price of 146.00 [3] - Innovent Biologics (1801 HK) with a target price of 60.00 and a current price of 59.55 [3] ASCO Conference Highlights - The 2025 ASCO conference featured 71 original research results from Chinese pharmaceutical companies, with 11 studies presented as Late Breaking Abstracts [5][6] - Companies like Innovent Biologics and Rongchang Biologics showcased promising clinical data for their innovative therapies [5][6] Investment Recommendations - The report recommends focusing on companies with strong growth potential and clear profitability timelines, such as Rongchang Biologics, Kangfang Biologics, and Innovent Biologics [4] - It also highlights the potential for prescription drug companies like Xiansheng Pharmaceutical and Hansoh Pharmaceutical to expand their valuations due to high growth rates [4] Recent Approvals and Developments - Rongchang Biologics received approval for a new indication for its drug in treating myasthenia gravis [20] - Innovent Biologics published positive results for its dual receptor agonist in a prominent medical journal [20] - BeiGene's clinical research for its drug in small cell lung cancer has shown promising results [20]

Market Overview - The FTSE China A50 Index component stocks showed a mixed performance with the semiconductor sector rising throughout the day while the automotive sector turned negative in the afternoon [1] Insurance Sector - China Life Insurance had a market capitalization of 358.657 billion with a trading volume of 1.868 billion, increasing by 1.35% - China Pacific Insurance had a market capitalization of 333.441 billion with a trading volume of 0.580 billion, increasing by 0.43% - Ping An Insurance had a market capitalization of 974.612 billion with a trading volume of 1.173 billion, decreasing by 1.22% [3] Alcohol Industry - Kweichow Moutai had a market capitalization of 1934.545 billion with a trading volume of 10.48 billion, decreasing by 0.12% - Wuliangye Yibin had a market capitalization of 229.085 billion with a trading volume of 20.36 billion, increasing by 0.32% - Shanxi Fenjiu had a market capitalization of 494.206 billion with a trading volume of 33.75 billion, increasing by 0.20% [3] Semiconductor Sector - Northern Huachuang had a market capitalization of 227.153 billion with a trading volume of 15.27 billion, increasing by 1.89% - Cambricon Technologies had a market capitalization of 255.859 billion with a trading volume of 26.75 billion, increasing by 0.48% [3] Automotive Sector - BYD had a market capitalization of 289.728 billion with a trading volume of 69.43 billion, decreasing by 0.48% - Great Wall Motors had a market capitalization of 1097.498 billion with a trading volume of 3.62 billion, decreasing by 0.13% - Beijing-Shanghai High-Speed Railway had a market capitalization of 195.928 billion with a trading volume of 3.67 billion, increasing by 0.34% [3] Energy Sector - COSCO Shipping had a market capitalization of 1520.904 billion with a trading volume of 6.46 billion, decreasing by 0.36% - Sinopec had a market capitalization of 694.943 billion with a trading volume of 13.18 billion, decreasing by 1.04% [3] Coal Industry - China Shenhua Energy had a market capitalization of 202.044 billion with a trading volume of 6.30 billion, decreasing by 0.05% - Shaanxi Coal and Chemical Industry had a market capitalization of 790.568 billion with a trading volume of 54.88 billion, increasing by 0.24% [3] Power Sector - China Yangtze Power had a market capitalization of 741.142 billion with a trading volume of 20.26 billion, increasing by 1.71% - China Nuclear Power had a market capitalization of 197.247 billion with a trading volume of 8.48 billion, decreasing by 0.79% [4] Food and Beverage Sector - Citic Securities had a market capitalization of 380.888 billion with a trading volume of 13.92 billion, increasing by 1.10% - Haitai Flavoring had a market capitalization of 248.170 billion with a trading volume of 5.66 billion, decreasing by 1.67% [4] Consumer Electronics - Heng Rui Medicine had a market capitalization of 391.220 billion with a trading volume of 34.65 billion, decreasing by 0.28% - Industrial Fulian had a market capitalization of 357.251 billion with a trading volume of 46.61 billion, increasing by 6.03% [4] Logistics Sector - Mindray Medical had a market capitalization of 174.350 billion with a trading volume of 7.04 billion, decreasing by 0.34% - SF Holding had a market capitalization of 232.046 billion with a trading volume of 11.09 billion, decreasing by 0.36% [4] Telecommunications - China Unicom had a market capitalization of 473.612 billion with a trading volume of 11.23 billion, increasing by 1.31% [4]

Group 1 - The National Vaccine and Biotechnology Index (980015) has seen a strong increase of 2.39% as of May 29, 2025, with notable gains in constituent stocks such as Zhaoyan New Drug (603127) up 9.99%, Yifan Pharmaceutical (002019) up 9.17%, and Dizhe Pharmaceutical (688192) up 8.73% [1] - The Biovaccine ETF (159657) rose by 2.28%, with the latest price reported at 0.63 yuan [2] - The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3, 2025, in Chicago, showcasing the development of oncology research in China, with over 70 studies from Chinese scholars selected for presentation [2] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of April 30, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and others, collectively accounting for 63.18% of the index [3] - The Biovaccine ETF closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [2]

"2020年1月启动研发，2022年6月启动国内关键Ⅰ期临床研究，2023年1月向国家药品监督管理局递 交创新药上市申请，该药品历时5年终于上市。"山东盛迪医药制剂研究所负责人郭创龙介绍，瑞格列汀 是中国首个自主研发的二肽基肽酶-4抑制剂类药品，二甲双胍则是常见降糖药，两者作用方式不同，很 多患者需同时服用。"而瑞格列汀二甲双胍片是两种单药的复方制剂，患者以后只需要服用这一种药即 可，减轻了患者服药负担。"郭创龙介绍。 该药品的上市，标志着山东盛迪医药有限公司在创新药研发领域取得重要突破。 又一1类创新药获批上市 济南现代医药产业动能澎湃 5月22日，国家药品监督管理局（NMPA）官网显示，山东盛迪医药有限公司申报的1类创新药瑞格 列汀二甲双胍片（I）/（II）（瑞霖唐）获批上市。这是该公司获批的首个1类创新药，也是济南第4款 创新药，将造福糖尿病患者。 糖尿病已经成为继肿瘤、心脑血管病之后，第三位严重危害人类健康的慢性疾病。该药品正是用于 治疗成人2型糖尿病的。 创新药陆续上市的背后，是近年来济南市大力发展现代医药产业的结果。 现代医药是济南市13条标志性产业链之一。近年来，该市先后出台多个政策文件支撑产业 ...

Group 1 - The recent surge in Chinese companies listing abroad, including major firms like CATL and Hengrui Medicine, reflects a growing trend in cross-border IPOs driven by improved regulatory efficiency and support from authorities [1][2][3] - As of May 28, 2023, 35 Chinese companies have gone public in the US, surpassing last year's total of 25, while 20 companies have listed in Hong Kong, exceeding last year's 16 [1] - The China Securities Regulatory Commission (CSRC) has significantly reduced the review time for overseas listing applications from over 100 days to under 60 days, with CATL achieving a record approval time of just 25 days [1] Group 2 - Consumer-oriented companies, particularly in the new beverage sector, are leading the wave of overseas listings, with several brands like Gu Ming and Mi Xue Group successfully listing in Hong Kong and the US [2] - There are currently 168 companies in the overseas listing application process, with 133 in the "supplementary materials" stage and 35 "accepted," primarily in sectors like new consumption, biomedicine, and new energy [2] - Deloitte predicts that by 2025, around 80 new stocks will be listed in Hong Kong, raising between HKD 130 billion to 150 billion, mainly from large A-share companies and tech firms [2] Group 3 - The "A+H" listing model is expanding, with companies like Muyuan Foods and Hengrui Medicine recently applying for H-share listings in Hong Kong, highlighting a trend of dual listings [3] - The increase in A-share companies listing in Hong Kong is attributed to strategic international expansion, regulatory conveniences, and improved liquidity in the Hong Kong market [3] Group 4 - The CSRC has introduced policies to enhance the overseas listing process, including the "惠港5条" policy, which aims to optimize the scope of stocks eligible for trading through the Shanghai-Hong Kong Stock Connect [3] - The Hong Kong Stock Exchange has lowered the listing thresholds for "A+H" shares and introduced a special channel for tech companies, encouraging more mainland firms to list in Hong Kong [3] Group 5 - The regulatory environment for overseas listings is expected to improve further, with the CSRC focusing on enhancing transparency and communication with international investors [4][5] - The People's Bank of China and the State Administration of Foreign Exchange are working on policies to facilitate cross-border financing for domestic companies, addressing concerns about the efficiency of fund management during overseas listings [5] Group 6 - International institutions are expressing support for the globalization of Chinese companies, with the Singapore Exchange enhancing its secondary listing framework to attract Chinese firms listed in Hong Kong and the US [6]

Core Viewpoint - Heng Rui Medicine's successful IPO on the Hong Kong Stock Exchange marks a significant milestone, raising approximately HKD 9.89 billion, the largest financing scale in the Hong Kong pharmaceutical sector since 2020, and reflects strong international investor interest in the company's innovative and global strategies [1] Group 1: Financial Performance - In 2024, the company's revenue and net profit attributable to shareholders are projected to reach RMB 27.985 billion and RMB 6.337 billion, representing year-on-year growth of 22.63% and 47.28% respectively, achieving record highs [2] - The first quarter of 2024 saw revenue and net profit of RMB 7.206 billion and RMB 1.874 billion, with year-on-year increases of 20.14% and 36.90% [2] - Sales revenue from innovative drugs reached RMB 13.892 billion, a year-on-year increase of 30.6%, accounting for nearly 50% of total revenue [2] Group 2: R&D and Innovation - The company has invested a total of RMB 46 billion in R&D, with RMB 1.533 billion spent in the first quarter of 2024 [2][3] - As of the end of 2024, the company has applied for 2,609 invention patents in Greater China and holds 1,084 authorized invention patents in the region, along with 753 authorized patents in Europe, the US, and Japan [3] - The company has launched 20 new molecular entity drugs and 4 other innovative drugs in China, with over 90 self-developed products currently in clinical development [3] Group 3: Internationalization Strategy - The company has secured EUR 160 million and USD 100 million in upfront payments through licensing agreements, indicating a strong internationalization strategy [4] - The internationalization approach focuses on deep participation in the global innovation chain rather than merely selling products, exemplified by a recent licensing deal with Kailera that includes a cash and equity component [4] - The company has initiated over 20 overseas clinical trials and received fast track and orphan drug designations from the FDA for several innovative drugs [4][5] Group 4: Future Growth Potential - The company is expected to maintain a compound annual growth rate of over 20% in revenue over the next three years, supported by a robust pipeline of innovative products [6] - The current pipeline includes over 49 disclosed target products and more than 40 undisclosed projects, covering various therapeutic areas such as oncology and cardiovascular diseases [6] - The strategic focus on cutting-edge fields like cell therapy and bispecific antibodies is anticipated to be a key catalyst for value re-evaluation [6] Group 5: Long-term Value Proposition - The company's growth trajectory is characterized by innovation-driven strategies and a commitment to internationalization, establishing a strong competitive moat [7] - The value proposition extends beyond current performance to include potential future blockbuster products and accumulated global influence [7] - The company is positioned to lead the transition of Chinese pharmaceutical companies from manufacturing to intelligent manufacturing, contributing to global healthcare solutions [7]